PNC Financial Services Group
KNTE

PNC Financial Services Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

PNC Financial Services Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-178
Closed -$2K – 4784
2022
Q1 		$2K Buy
+178
New +$1.96K ﹤0.01% 4248
2021
Q4 		– Sell
-11
Closed – – 4662
2021
Q3 		$0 Buy
+11
New +$239 ﹤0.01% 4439

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PNC Financial Services Group's KNTE Position: Q2 2022 in Review

PNC Financial Services Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2022, closing a stake of 178 shares — an estimated $2K sold.

PNC Financial Services Group first reported a position in KNTE in Q3 2021 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 73 funds tracked by Wall St. Rank hold KNTE as of Q2 2022.

  • PNC Financial Services Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • PNC Financial Services Group sold 178 Kinnate Biopharma Inc. Common Stock shares in Q2 2022, an estimated $2K.
  • PNC Financial Services Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • PNC Financial Services Group's Kinnate Biopharma Inc. Common Stock position peaked at $2K in Q1 2022.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2022.

Based on PNC Financial Services Group's 13F filing for Q2 2022, filed 12 Aug 2022.